Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | TLR2 | O60603 | 3/20 | 0.51 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MDM4 | O15151 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15750412 | 1.00 | KMT2A (0.53) | KMT2ATLR2TLR1MDM2MEN1 | |
| SCHEMBL31522724 | 1.00 | KMT2A (0.53) | KMT2ATLR2TLR1MDM2MEN1 | |
| SCHEMBL12264511 | 0.93 | KMT2A (0.52) | KMT2ATLR2TLR1MDM2MEN1 | |
| SCHEMBL27261267 | 0.93 | TLR2 (0.54) | KMT2ATLR2TLR1MDM2MEN1 | |
| SCHEMBL30783495 | 0.93 | TLR2 (0.54) | KMT2ATLR2TLR1MDM2MEN1 | |
| SCHEMBL13339086 | 0.93 | MDM2 (0.49) | KMT2ATLR2TLR1MDM2MDM4 | |
| SCHEMBL12506772 | 0.92 | TLR2 (0.53) | KMT2ATLR2TLR1MDM2MEN1 | |
| SCHEMBL2292778 | 0.92 | MDM2 (0.59) | KMT2ATLR2TLR1MDM2ALDH1A1 | |
| SCHEMBL2736294 | 0.92 | TLR2 (0.53) | KMT2ATLR2TLR1MDM2MEN1 | |
| SCHEMBL1738182 | 0.92 | MDM2 (0.59) | KMT2ATLR2TLR1MDM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230131121-A1 | BRANCHED DISCRETE PEG CONSTRUCTS | AUDAX PRIVATE DEBT LLC, AS AGENT | 2023-04-27 | — | — | US | disclosed |
| US-20170313656-A1 | Branched Discrete PEG Constructs | QUANTA BIODESIGN, LTD. | 2017-11-02 | — | — | US | disclosed |
| EP-2309989-B1 | DRUG LOADED POLYMERIC NANOPARTICLES AND METHODS OF MAKING AND USING SAME | BIND THERAPEUTICS INC (US) | 2016-09-07 | — | — | EP | disclosed |
| US-20130052130-A1 | Branched Discreet PEG Constructs | UNIVERSITY OF WASHINGTON (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313656-A1 | Branched Discrete PEG Constructs | BTD, IDUA, DNPEP | KMT2A 3152/4885TLR2 983/4885TLR1 850/4885 |
| US-20230131121-A1 | BRANCHED DISCRETE PEG CONSTRUCTS | BTD, IDUA, DNPEP | KMT2A 3009/4885TLR2 961/4885TLR1 847/4885 |
| US-20130052130-A1 | Branched Discreet PEG Constructs | BTD, DNPEP, IDUA | KMT2A 2440/4885TLR2 1044/4885TLR1 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.